BOLD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

BOLD ▼ -11.25% at T+20d

LONG call ✗ call lost -11.25% · α vs SPY -15.45% · entry $1.60 → $1.42

Next anchor: T+60d in 5w

Currently $1.40 · -12.50% from $1.60 entry

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

-1.25%

call -1.25% · α -0.60%

$1.58

settled 7w ago

T+5d

-8.13%

call -8.13% · α -9.04%

$1.47

settled 7w ago

T+20d

-11.25%

call -11.25% · α -15.45%

$1.42

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Boundless Bio (BOLD) announced preclinical data for its lead candidate BBI-940, a novel oral kinesin degrader targeting extrachromosomal DNA (ecDNA)-positive cancers, presented at AACR 2026. The data show potent antitumor activity in breast cancer models, supporting ongoing Phase 1 trials in ER+/HER2- and TNBC-LAR subtypes.

Actionable Insight

Preclinical data validate BBI-940's novel mechanism in a high-unmet-need population (ecDNA+ cancers). While still early, this could reprice BOLD shares if the Phase 1 trial shows signs of clinical activity. Monitor for dose escalation updates and biomarker responses from KOMODO-1 trial in 2026–2027.

Key Facts

Presented preclinical data at AACR 2026 demonstrating BBI-940's mechanism: selective degradation of a novel kinesin target disrupts ecDNA segregation and causes tumor cell death.
BBI-940 showed 32% sensitivity in breast cancer cell lines, including those with ecDNA and FGFR1 gain.
In vivo data show monotherapy tumor regressions in ecDNA+ TNBC-LAR models and strong combination activity in ecDNA+/FGFR1+ ER+ models.
BBI-940 is currently in Phase 1 KOMODO-1 trial (NCT07408089) in advanced/metastatic breast cancer patients.
No human efficacy or safety data reported yet — still early-stage development.

Financial Impact

Non-dilutive, preclinical-stage catalyst with potential to increase valuation if clinical data de-risk development

pipeline valueR&D focusinvestor sentiment

Risk Factors

Early-stage development: Phase 1 trial ongoing with no clinical data yet — high risk of failure.
Novel target and mechanism: unproven in humans, potential for unexpected toxicity or lack of efficacy.
Low market cap ($37M): high volatility, sensitive to clinical updates and financing needs.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3276505

4 reports for BOLD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for BOLD — sortable, filterable
	Type				Now
May 8, 2026 4w ago	8-K NEUTRAL ★ 3/10	$1.44 $1.42	▼ −1.39%	▼ −1.41%	$1.40 (−2.78%)
May 8, 2026 4w ago	Press Release BEARISH ★ 6/10	$1.44 $1.42	▲ +1.39%	▲ +1.41%	$1.40 (+2.78%)
Apr 17, 2026 7w ago	Press Release BULLISH ★ 7/10	$1.60 $1.42	▼ −11.25%	▼ −15.45%	$1.40 (−12.50%)
Apr 13, 2026 8w ago	8-K BEARISH ★ 7/10	$1.56 $1.55	▲ +0.64%	▲ +6.94%	$1.40 (+10.26%)

US Market Status

Market Closed — Opens Thu (10h 9m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access